Table 2 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Safety overview, including the most common treatment-related imAE and TRAE (occurred in ≥10% of patients with MSS mCRC NLM; N = 123).